A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
about
Regulation of glucose homeostasis by GLP-1Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structureThe class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitusSystems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor SystemOral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activitiesReversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese miceGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesNovel Allosteric Modulators of G Protein-coupled ReceptorsGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideGlucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domainHuman GLP-1 receptor transmembrane domain structure in complex with allosteric modulators.Synthesis of antibacterial 1,3-diyne-linked peptoids from an Ugi-4CR/Glaser coupling approachBoc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic miceSynthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery.Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist.Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward.Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.A peptidomics strategy to elucidate the proteolytic pathways that inactivate peptide hormones.A novel glucagon-like peptide 1 peptide identified from Ophisaurus harti.Characterization of synapses in the rat subnucleus centralis of the nucleus tractus solitarius.Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.Emergence of Chinese drug discovery research: impact of hit and lead identification.Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes?Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice.Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discoveryDifferential Requirement of the Extracellular Domain in Activation of Class B G Protein-coupled ReceptorsDipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetesJuxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.CNS regulation of plasma cholesterol.The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.The future of incretin-based therapy: novel avenues--novel targets.
P2860
Q24563430-980024DB-AC43-4666-BAC2-3463C2E98BC0Q26798049-B53DCC6D-C1E2-4A72-B8AA-9ECD4DB659D3Q26828940-F0B85D80-D540-4901-A0F5-6DA6710D5C54Q26999386-4A3EABA8-5ADD-4A04-8E60-9819AE2137E6Q27023585-1D2B4C83-522A-43D5-8188-962ECDD83909Q27027240-15575FA6-C4F6-4DD5-BCED-0923F049EBF6Q27316004-550E8F37-27C3-4D3B-97FB-D05F22DBF679Q28067465-47A6D169-593C-4A73-89F8-21378AB9BA80Q28081112-9D05FC83-33D8-488A-92B1-732E7D92ACD6Q28081671-C559AAB8-1E48-4388-93AE-F3190874A327Q28542687-D2699847-7CEF-4495-9199-F88DDB03A7C7Q30179454-52412E18-6BFB-4F43-BF8C-365D904E7E74Q30316783-5D018D34-82CB-4453-B342-D1745E0AE3CAQ33358112-994A9EA9-7541-4054-9E74-A1DD5F7E2BA4Q33593241-CD83553F-B34F-4AAD-BA35-2B7315D195D8Q33646569-CE2251BE-3577-49A1-991D-743AAA754844Q33697296-9D4C2B72-8400-4282-9530-24E7A95D445EQ34342677-D34D945C-65F8-4B35-9B71-79D906A18467Q34355248-852448DD-EE61-4D6D-A227-1705608EC52EQ34795373-71006597-DF59-4D98-96E2-88A144940F26Q34871648-26D0D1D6-3079-4E2D-8DB9-74D0241B8CDBQ34980550-14BEC861-2764-454B-9CC3-C5C936B7E59CQ35087846-25081701-6536-442F-985A-8323EA5BB2ABQ35454522-09CE3476-2FC3-4C1D-8629-8F863E9E5A4AQ35529100-34F77AC5-2F34-471C-BE96-BE16B6B6D4ECQ35612166-8DE63373-E145-46A1-B6E9-E7C720AAC770Q35778284-F7FCC647-7F10-4F7F-AA46-12D332B3F104Q36306579-C4ACDDC7-4418-4DD7-AA62-9574C37506B0Q36971308-69D55A2B-6D6F-4194-BDB4-E612816EE9D5Q37050373-0A4D41AB-0ABA-4785-A1FF-CADFC78C734AQ37098923-F39CC4D6-F394-4040-A0B6-B4D37363653FQ37105326-B02CD74C-11B1-4BDD-9B5B-D28DE00B69CEQ37311302-87F7AC80-5635-4E6E-A306-BF8D4CA62ABEQ37372130-312A6FBB-9950-4755-807F-AC19962CB68EQ37395298-48B9406E-43B0-4016-91C2-B55E66836961Q37410215-AF08C0CE-9E1C-483F-97A6-F250A1A095C8Q37430684-91520533-F6BE-40F9-9A56-9ACA1E6EEDE6Q37897218-8AE323DE-5990-4F68-BCF6-1BACE3B15321Q37910818-1C053A2F-6C31-4A8E-BADE-351484D85F34Q37913528-463F6516-86E6-4800-BBAD-495917818BA6
P2860
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@ast
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@en
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@nl
type
label
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@ast
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@en
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@nl
prefLabel
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@ast
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@en
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@nl
P2093
P2860
P356
P1476
A nonpeptidic agonist of gluca ...... ficacy in diabetic db/db mice.
@en
P2093
Andrew A Young
Caihong Zhou
Guangxing Wang
Jiayu Liao
Kaixian Chen
Ming-Wei Wang
P2860
P304
P356
10.1073/PNAS.0610173104
P407
P50
P577
2007-01-09T00:00:00Z